Rabbit Recombinant Monoclonal AKT3 antibody - conjugated to HRP. Suitable for WB and reacts with Mouse, Rat, Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
WB | |
---|---|
Human | Tested |
Mouse | Tested |
Rat | Tested |
Xenopus tropicalis | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/5000 | Notes - |
Species Rat | Dilution info 1/5000 | Notes - |
Species Human | Dilution info 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Xenopus tropicalis | Dilution info - | Notes - |
Select an associated product type
AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis.
RAC-beta serine/threonine-protein kinase, AKT3
PKBG, AKT3, RAC-gamma serine/threonine-protein kinase, Protein kinase Akt-3, Protein kinase B gamma, RAC-PK-gamma, STK-2, PKB gamma
Rabbit Recombinant Monoclonal AKT3 antibody - conjugated to HRP. Suitable for WB and reacts with Mouse, Rat, Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
AKT1 AKT2 and AKT3 also known as Protein Kinase B (PKB) isoforms are serine/threonine-specific protein kinases with critical roles in cellular processes. AKT1 has a molecular weight of about 55.8 kDa AKT2 weighs approximately 56.1 kDa and AKT3 typically has a similar mass. These proteins are expressed in many tissues including brain and heart with AKT1 ubiquitously present AKT2 focused in insulin-responsive tissues and AKT3 mainly in the brain. The molecular weight of AKT plays an important role in their functionality and specificity in tissues.
AKT proteins regulate cell cycle growing cell survival proliferation and metabolism. They participate as core components of the PI3K/AKT/mTOR signaling pathway forming complexes with other proteins to transmit signals. They bind to phosphoinositide lipids on the cell membrane facilitating their activation and downstream signaling. Through these activities the AKT transporter proteins maintain cellular homeostasis and play a part in stress response.
AKT proteins engage in important signaling networks including the PI3K/AKT pathway and mTOR pathway. They work closely with PI3K and mTOR proteins coordinating cellular growth and energy metabolism. In particular the AKT pathway responds to growth factors and insulin influencing glucose uptake and glycolysis regulation through interaction with proteins such as glycogen synthase kinase 3 (GSK3).
Dysregulation of AKT signaling can lead to cancer and diabetes. High AKT activation correlates with various cancers by promoting cell survival and growth. In diabetes impaired AKT2 regulation disrupts glucose uptake affecting insulin response. AKT's relationship with mTOR is significant as it often influences tumor growth and progression in cancerous tissues.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab200854 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-AKT1 + AKT2 + AKT3 antibody [EPR16798] (ab200854) at 1/5000 dilution
Lane 1: Kidney (Human) Tissue Lysate - fetal normal tissue at 10 µg
Lane 2: Brain (Mouse) Tissue Lysate at 10 µg
Lane 3: Brain (Rat) Tissue Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 56 kDa
Observed band size: 56 kDa
Exposure time: 1min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com